| Date | Time | Source | Headline | Symbol | Company |
| 05/15/2024 | 2:30PM | iHub Newswire | FeaturedIntegrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share | | |
| 03/18/2024 | 2:45PM | Edgar (US Regulatory) | Form 15-12G - Securities registration termination [Section 12(g)] | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 03/12/2024 | 4:55PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 03/11/2024 | 12:15AM | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 03/08/2024 | 1:39PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 03/08/2024 | 1:34PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 03/08/2024 | 1:29PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 03/08/2024 | 1:24PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 03/08/2024 | 1:20PM | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 03/07/2024 | 1:23PM | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration statement | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 03/07/2024 | 8:49AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 03/06/2024 | 4:05PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 02/23/2024 | 2:09PM | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 02/22/2024 | 8:31AM | Edgar (US Regulatory) | Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 02/22/2024 | 8:30AM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 02/12/2024 | 1:43PM | PR Newswire (US) | Kuehn Law Encourages AMAM, DOOR, CBAY, and WISH Investors to Contact Law Firm | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 01/10/2024 | 3:07PM | PR Newswire (US) | Kuehn Law Encourages AMAM, HARP, AXNX, and CPE Investors to Contact Law Firm | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 01/08/2024 | 2:54PM | Dow Jones News | Trending: Johnson & Johnson and Merck & Co. Announce Acquisitions | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 01/08/2024 | 10:04AM | Dow Jones News | Ambrx Biopharma Shares Double on $2 Billion Acquisition by Johnson & Johnson | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 01/08/2024 | 8:12AM | Dow Jones News | Johnson & Johnson to Acquire Cancer-Treatment Developer Amrbx for $2 Billion | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 10/23/2023 | 5:19PM | Edgar (US Regulatory) | Form 15-12G - Securities registration termination [Section 12(g)] | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 09/15/2023 | 4:27PM | Edgar (US Regulatory) | Form DEFM14A - Definitive proxy statement relating to merger or acquisition | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 09/15/2023 | 4:24PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 09/06/2023 | 4:05PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 08/25/2023 | 5:23PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 07/19/2023 | 9:49AM | Dow Jones News | Ambrx Biopharma Gets Fast Track Designation for ARX517 Cancer Treatment | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 06/28/2023 | 4:46PM | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 06/28/2023 | 4:45PM | Edgar (US Regulatory) | Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 06/28/2023 | 4:07PM | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:AMAM | Ambrx Biopharma Inc |
| 06/28/2023 | 4:06PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:AMAM | Ambrx Biopharma Inc |